Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]
Discontinued
Reference number: GID-TAG507
A final appraisal determination (FAD) for the technology appraisal of dinutuximab for treating high-risk neuroblastoma [ID799] was sent to consultees and commentators on Thursday 24 March 2016. In the time period since issuing the FAD to consultees and commentators, the company that markets dinutuximab (United Therapeutics Corporation), has requested to make a further submission including a patient access scheme. In recognition of the exceptional nature of this request, NICE has agreed that the appraisal can be referred back to the appraisal committee. The appeal stage of this appraisal topic has been suspended. This will allow the company to submit, and the appraisal committee to consider, the new evidence. We are withdrawing the FAD, it will not be published on our web site and its content remains confidential.